IL308465A - SARS-COV-2 polypeptides - Google Patents
SARS-COV-2 polypeptidesInfo
- Publication number
- IL308465A IL308465A IL308465A IL30846523A IL308465A IL 308465 A IL308465 A IL 308465A IL 308465 A IL308465 A IL 308465A IL 30846523 A IL30846523 A IL 30846523A IL 308465 A IL308465 A IL 308465A
- Authority
- IL
- Israel
- Prior art keywords
- cov
- sars
- polypeptides
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190964P | 2021-05-20 | 2021-05-20 | |
| US202263341771P | 2022-05-13 | 2022-05-13 | |
| PCT/US2022/030068 WO2022246084A1 (en) | 2021-05-20 | 2022-05-19 | Sars-cov-2 polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308465A true IL308465A (en) | 2024-01-01 |
Family
ID=82321637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308465A IL308465A (en) | 2021-05-20 | 2022-05-19 | SARS-COV-2 polypeptides |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220370601A1 (enExample) |
| EP (1) | EP4294440A1 (enExample) |
| JP (1) | JP2024521098A (enExample) |
| KR (1) | KR20240012394A (enExample) |
| AU (1) | AU2022277697A1 (enExample) |
| BR (1) | BR112023024034A2 (enExample) |
| CA (1) | CA3212678A1 (enExample) |
| IL (1) | IL308465A (enExample) |
| MX (1) | MX2023013665A (enExample) |
| WO (1) | WO2022246084A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240042070A1 (en) * | 2022-06-28 | 2024-02-08 | Transcode Therapeutics, Inc. | Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy |
| CN115947801A (zh) * | 2022-12-29 | 2023-04-11 | 中国疾病预防控制中心病毒病预防控制所 | 一种流感病毒通用和冠状病毒联合多肽及其疫苗的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102831970B1 (ko) * | 2020-04-02 | 2025-07-11 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 |
| CN113874507A (zh) * | 2020-04-09 | 2021-12-31 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
| EP4138876A1 (en) * | 2020-04-23 | 2023-03-01 | ISA Pharmaceuticals B.V. | Immunization against sars-cov-related diseases |
| GB202011652D0 (en) * | 2020-07-28 | 2020-09-09 | Univ Oxford Innovation Ltd | Polypeptide panels and uses thereof |
| US11191827B1 (en) * | 2020-12-09 | 2021-12-07 | Tevogen Bio Inc. | COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19 |
-
2022
- 2022-05-19 US US17/748,715 patent/US20220370601A1/en active Pending
- 2022-05-19 WO PCT/US2022/030068 patent/WO2022246084A1/en not_active Ceased
- 2022-05-19 EP EP22735677.1A patent/EP4294440A1/en active Pending
- 2022-05-19 KR KR1020237039921A patent/KR20240012394A/ko active Pending
- 2022-05-19 AU AU2022277697A patent/AU2022277697A1/en active Pending
- 2022-05-19 BR BR112023024034A patent/BR112023024034A2/pt unknown
- 2022-05-19 JP JP2023571758A patent/JP2024521098A/ja active Pending
- 2022-05-19 IL IL308465A patent/IL308465A/en unknown
- 2022-05-19 CA CA3212678A patent/CA3212678A1/en active Pending
- 2022-05-19 MX MX2023013665A patent/MX2023013665A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4294440A1 (en) | 2023-12-27 |
| MX2023013665A (es) | 2024-01-08 |
| CA3212678A1 (en) | 2022-11-24 |
| AU2022277697A1 (en) | 2024-01-04 |
| BR112023024034A2 (pt) | 2024-02-06 |
| US20220370601A1 (en) | 2022-11-24 |
| WO2022246084A1 (en) | 2022-11-24 |
| JP2024521098A (ja) | 2024-05-28 |
| KR20240012394A (ko) | 2024-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289122A (en) | polypeptides | |
| IL289119A (en) | polypeptides | |
| GB202017649D0 (en) | Polypeptide | |
| GB202007441D0 (en) | Polypeptide | |
| IL317214A (en) | New polypeptides | |
| GB202007532D0 (en) | Polypeptides | |
| IL299811A (en) | polypeptide | |
| GB201820556D0 (en) | Novel polypeptides | |
| IL308465A (en) | SARS-COV-2 polypeptides | |
| SG11202102378WA (en) | Arginase1 polypeptides | |
| GB202315671D0 (en) | Polypeptides | |
| GB202219576D0 (en) | Polypeptides | |
| GB202019908D0 (en) | Cripr polypeptides | |
| GB201913804D0 (en) | Fusion polypeptides | |
| GB202019879D0 (en) | Polypeptide | |
| GB202111640D0 (en) | Polypeptides | |
| GB202012736D0 (en) | Polypeptides | |
| GB202102758D0 (en) | Modified polypeptides | |
| GB201900621D0 (en) | Labelled polypeptides | |
| GB202312099D0 (en) | Polypeptides | |
| GB202211575D0 (en) | Polypeptides | |
| GB201911708D0 (en) | Polypeptides | |
| GB202119034D0 (en) | Polypeptide | |
| GB202105924D0 (en) | Polypeptide | |
| GB202103001D0 (en) | Polypeptide |